AEGiS-11IAC: Effect of monthly transfusion of human IVIG and cross-matched peripheral blood mononuclear cells in late-stage AIDS patients.

11th International AIDS Conference


Vancouver, British Columbia — July 7-12, 1996

Print this Article


Effect of monthly transfusion of human IVIG and cross-matched peripheral blood mononuclear cells in late-stage AIDS patients.

Int Conf AIDS 1996 Jul 7-12; 11:220 (abstract no. Th.B.172)
Gomatos PJ, Reiter WM, Keller RH, Tomaka F, Giannetti B, Uribe MR; Center for Special Immunology, Ft. Lauderdale, FL, USA. Fax: 954-767-9443.

OBJECTIVE: To determine the effect in late-stage AIDS patients of monthly transfusion (TR) of human IVIG and cross-matched (X-matched) peripheral blood mononuclear cells (PBMC).

METHODS: Patients with late-stage AIDS received monthly TR of 12-15g of human IVIG followed by 1-4 x 109 X-matched PBMC from single haplotype-matched donors if no ALLO anti-lymphocyte IgG antibodies were detected in major X-match.

RESULTS: 19 patients received at least one round of IVIG followed by PBMC TR [total 128 TR; range 1-25/pt]: 8 continue, 5 withdrew and 6 expired from AIDS progression unrelated to PBMC TR [3/6 had received only one PBMC TR]. 7/19 had KS at entry: in no subject compliant in monthly PBMC TR and anti-KS chemotherapy did KS progress significantly. Mean lymphocyte count decreased from 745/microliter (162-1280) at baseline to 605/microliter (92-1099) during enrollment; mean CD4+ cell count from 24/microliter (0-75) to 17/microliter (0-76) and mean CD8+ cell count from 444microliter (89-665) to 358/microliter (43-822). Mean p24 Ag increased from 176 to 254 pg/ml. Plasma HIV copy number (RNA PCR) remained stable during 6-16 mos after entry, or increased less than one log10. Group mean QOL measured by the 30-item (11 measures) RAND MOS Health Ratings questionnaire remained stable (2-16 mos).

CONCLUSION: Monthly TR of human IVIG followed by X-matched PBMC was well-tolerated. During enrollment, mean QOL and immunological parameters remained essentially stable. During 6-16 months of study, plasma HIV copy number remained stable or increased less than one log10.

Keywords: AEGIS, Acquired Immunodeficiency Syndrome, CD4 Lymphocyte Count, Blood Grouping and Crossmatching, HIV, Immunoglobulins, Intravenous, HIV Infections, Anti-HIV Agents, Polymerase Chain Reaction, HIV Seropositivity, HIV Core Protein p24, Case-Control Studies, Human, ICA11

960707
ThB172

Copyright © 1996 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.